Eri Kato - Concepedia

Author

Eri Kato

Kyoto University ORCID

Also Known As

Chakraborty, E KATO, E Kato, E Kato Jr, E. T. Kato, ERI T. KATO, Eri KATO, Eri Kato, Eri T Kato, Eri T. Kato

Publications

12.4K

Citations

H-Index

Concepts

All Affiliations

Kyoto University Thrombolysis in Myocardial Infarction Study Group Brigham and Women's Hospital Kobe City Medical Center General Hospital Kurashiki Central Hospital

About

Eri Kato is an author at Kyoto University specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.2K
2	Public Health	4	4	152
3	Diabetes	2	2	689
4	Epidemiology	2	2	51
5	Gastroenterology	1	1	35

Eri Kato

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, New England Journal of Medicine	2018	6K
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn, The Lancet Diabetes & Endocrinology Metabolic SyndromeDeclare–timi 58Diabetes ManagementRenal DiseaseChronic Kidney Disease	2019	656
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus Eri Kato, Michael G. Silverman, Ofri Mosenzon, Circulation	2019	550
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial Eri Kato, Robert P. Giugliano, Christian T. Ruff, Journal of the American Heart Association	2016	275
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, American Heart Journal Metabolic SyndromeHypertensionCardiovascular DiseaseDapagliflozin EffectPharmacology	2018	179
The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study Eri Kato, Tetsuji Sawada, Koichiro Tahara, International Journal of Rheumatic Diseases	2017	141
<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics Itamar Raz, Ofri Mosenzon, Marc P. Bonaca, Diabetes Obesity and Metabolism	2018	108
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure Takeshi Kitai, Shun Kohsaka, Takao Kato, Circulation Journal Heart FailureCardiorenal SyndromesCardiovascular DiseaseStructural Heart DiseaseCardiac Care	2025	98
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases Masakazu Yamagishi, Nagara Tamaki, Takashi Akasaka, Circulation Journal Health PolicyCardiovascular DiseaseDiagnosisCardiac CarePreventive Cardiology	2021	89
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Eri Kato, Christopher P. Cannon, Michael A. Blazing, Journal of the American Heart Association	2017	71

Page 1